{"id":837478,"date":"2025-04-15T09:11:51","date_gmt":"2025-04-15T13:11:51","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/"},"modified":"2025-04-15T09:11:51","modified_gmt":"2025-04-15T13:11:51","slug":"scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/","title":{"rendered":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada"},"content":{"rendered":"<div class=\"mw_release\">\n<ul>\n<li style=\"text-align:justify\">ELYXYB<sup>\u00ae<\/sup> is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.<sup>1<\/sup><\/li>\n<li>According to market data from 2018, it was found that migraine was more severe than other types of headaches and it impacted more than 2.7 million Canadians, with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.<sup>2 <\/sup><\/li>\n<li>There is strong evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for migraine. ELYXYB<sup>\u00ae<\/sup> (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.<sup>3<\/sup><\/li>\n<\/ul>\n<p align=\"justify\">PALO ALTO, Calif., April  15, 2025  (GLOBE NEWSWIRE) &#8212; Scilex Holding Company (Nasdaq: SCLX, \u201cScilex\u201d or \u201cCompany\u201d), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, neurodegenerative and cardiometabolic disease, today announced that it has received approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB<sup>\u00ae<\/sup>\u2019s acute treatment of migraine with or without aura in Canada.<\/p>\n<p>Clinicians in a recent market research study expressed their desire for fast and safe alternatives for two large pools of acute migraine patients \u2013 those who have an insufficient response to triptan therapy, and those who have contraindications to triptan use. ELYXYB<sup>\u00ae<\/sup>\u2019s product profile mapped with a high degree of certainty to these stated unmet needs. In clinical studies, patients treated with ELYXYB<sup>\u00ae<\/sup> demonstrated pain relief in as little as 15 minutes, and significant pain relief compared to placebo within 45 minutes in approximately 50% of patients.<sup>4,5<\/sup><\/p>\n<p align=\"justify\">\u201cWe welcome the approval of ELYXYB<sup>\u00ae<\/sup> (celecoxib oral solution) to the acute treatment options for nearly five million Canadians living with migraine. This unique option has proven efficacy and safety that can help patients achieve rapid pain freedom,\u201d\u00a0said Dr. Christine Lay, Professor of Neurology and Founding Director of the Headache program at the University of Toronto.<\/p>\n<p align=\"justify\">\u201cCanada is consistently among the top 10 global pharmaceutical markets. It is the second largest export destination for U.S. pharmaceuticals. It is also a strategic market for expansion globally, providing opportunities for increased international recognition and regulatory harmonization. We are very excited to expand the use of ELYXYB<sup>\u00ae<\/sup> to Canada, which is especially meaningful given the drug is manufactured in Canada, and to start helping Canadian patients who suffer from acute migraine,\u201d said Dmitri Lissin, MD, SVP and Chief Medical Officer of Scilex.<\/p>\n<p>For more information on Scilex Holding Company, refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_Tj5_S5vO84Kc-pzcBZUtbW_ZkUkqP_i9KVjum-v6SsVKOo7f3eJwgCWFB73VoNNaZARhuvzt54xsyxEwgQNULOPxJuIZyNys__eLYzAVE=\" rel=\"nofollow\" target=\"_blank\"><u>www.scilexholding.com<\/u><\/a><\/p>\n<p>For more information on Semnur Pharmaceuticals, Inc., refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_Tj5_S5vO84Kc-pzcBZUmYw8pXoLW9oHLmBP1rj_xK0YRqs3WMdbihAZKW0tF_u0opVP6Qwu2uVi37FV2JG16sVV_QxOJPFjBJsKKGmMTI=\" rel=\"nofollow\" target=\"_blank\"><u>www.semnurpharma.com<\/u><\/a><\/p>\n<p>For more information on ZTlido<sup>\u00ae<\/sup>, including Full Prescribing Information, refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=6DbbQAjYds3YRBKIMnTMqBczZizl5JaAwAr60ylBMJOVAvRK4gzPr-G1psSRrL_ScuhbRmu60Gco4w-VtuvEHA==\" rel=\"nofollow\" target=\"_blank\"><u>www.ztlido.com<\/u><\/a><\/p>\n<p>For more information on ELYXYB<sup>\u00ae<\/sup>, including Full Prescribing Information, refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=xJ-PhxmwWbhjLRORbWqoGkuuSQ98Kdzi4PqigYrUJagYBnIbGk-5X1QmUoqHAS52ydWMipQxFAtpuTSfH_M3IA==\" rel=\"nofollow\" target=\"_blank\"><u>www.elyxyb.com<\/u><\/a><\/p>\n<p>For more information on Gloperba<sup>\u00ae<\/sup>, including Full Prescribing Information, refer to <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ahHhMl1rRS05O3GGdANutWgjSbYw5CD7z-6kriQk5hh62Nl2g7CyUccbnw0Lrep-ulqoM9OBmo_OsDAY-Xeci08iGmgNIr5_Hdct4d6gJ9Y=\" rel=\"nofollow\" target=\"_blank\"><u>www.gloperba.com<\/u><\/a><\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1x165yGQt3p83zN4FnLM0CXeKloe7rhePGaYraHs4dcrkO0O3gxy33PGr9xeu-wCLevpd0Xk0i2LU7-zRumG9-7egDv7qfs0WsqKVprGegdJImzka887RVITHMzbkqNLUk_hsLBxyBXqVAU6utdRjg==\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>https:\/\/www.facebook.com\/scilex.pharm<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1x165yGQt3p83zN4FnLM0IjzdsuvjE7nVjEZRAgIB0bwW76eIkKRGHSdbwDkAG4asDeVS8ljxUUwXqx3hgF5VO9aya2ydFJNS9Co8KG3YE5JWIatgxnXto8DXCgAyX4eT8PXobvnsP8mlewuOyIyn4OIXUQcELUjourtZ-jafO-ZbYHJg5sfcyiTWvTHJngm\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>https:\/\/www.linkedin.com\/company\/scilex-holding-company\/<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=3vT0_VgordUtXVEZ762gQ5xdG9lG8cFDVPcW69LHY0gXed08VzVZp3jOdgYTccVG5omMBK3p-jIaKOmeWgdiE0uAd2TSvdDDXjYE_xBKn2A=\" rel=\"nofollow\" target=\"_blank\"><br \/>\n          <u>info@scilexholding.com<\/u><br \/>\n        <\/a>\n      <\/p>\n<p>\n        <strong>About Scilex Holding Company <\/strong>\n      <\/p>\n<p>Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain and, following the formation of its proposed joint venture with IPMC Company, in neurodegenerative and cardiometabolic disease. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex\u2019s commercial products include: (i) ZTlido<sup>\u00ae<\/sup> (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the \u201cFDA\u201d) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB<sup>\u00ae<\/sup>, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba<sup>\u00ae<\/sup>, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults.<\/p>\n<p>In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (\u201cSEMDEXA\u201d or \u201cSP-102\u201d), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (\u201cSP-103\u201d), a next-generation, triple-strength formulation of ZTlido, for the treatment of acute pain and for which Scilex has recently completed a Phase 2 trial in acute low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (\u201cSP-104\u201d), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia.<\/p>\n<p>Scilex Holding Company is headquartered in Palo Alto, California.<\/p>\n<p>\n        <strong>About Semnur Pharmaceuticals, Inc.<\/strong>\n      <\/p>\n<p>Semnur Pharmaceuticals, Inc. (\u201cSemnur\u201d), a wholly-owned subsidiary of Scilex, is a clinical late-stage specialty pharmaceutical company focused on the development and commercialization of novel non-opioid pain therapies. Semnur\u2019s product candidate, SP-102 (SEMDEXA\u2122), is the first non-opioid novel gel formulation administered epidurally in development for patients with moderate to severe chronic radicular pain\/sciatica.<\/p>\n<p>Semnur Pharmaceuticals, Inc. is headquartered in Palo Alto, California<\/p>\n<p>\n        <strong>Forward-Looking Statements<\/strong>\n      <\/p>\n<p>This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding the estimates for the migraine therapeutic market and the patient population for migraine in\u00a0Canada, ELYXYB\u2019s potential to further expand Scilex\u2019s non-opioid portfolio and its potential to address high unmet needs in treating acute migraine,\u00a0Scilex\u2019s proposed joint venture with IPMC Company and the potential development and commercialization of treatments for obesity, neurodegenerative, and cardiometabolic disease.<\/p>\n<p>Risks and uncertainties that could cause Scilex\u2019s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: Scilex\u2019s ability to gain market acceptance of ELYXYB<sup>\u00ae<\/sup> in Canada; Scilex\u2019s ability to consummate a joint venture or any other transaction with IPMC Company and develop and commercialize treatments for obesity, neurodegenerative, or cardiometabolic disease; risks associated with the unpredictability of trading markets and whether a market will be established for Scilex\u2019s common stock; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex\u2019s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex\u2019s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA\u2122), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex\u2019s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex\u2019s Annual Report on Form 10-K for the year ended December 31, 2024 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file with the SEC, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law.<\/p>\n<p align=\"justify\">\n        <strong>Contacts:<\/strong><br \/>\n        <br \/>Investors and Media<br \/>Scilex Holding Company <br \/>960 San Antonio Road<br \/>Palo Alto, CA 94303<br \/>Office: (650) 516-4310<\/p>\n<p>Email: investorrelations@scilexholding.com<\/p>\n<p>Website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=X_Tj5_S5vO84Kc-pzcBZUtbW_ZkUkqP_i9KVjum-v6QfY-HC8pZjdZEY24Uqz9-EZY5c77vakT5jIKNqUxMbOz97Dowf2tY9X0B9n9XlsE8=\" rel=\"nofollow\" target=\"_blank\"><u>www.scilexholding.com<\/u><\/a><\/p>\n<p>\n        <strong>Reference<\/strong>\n      <\/p>\n<p>1)\u00a0 Source: Celecoxib Oral Solution Approved for Acute Migraine March 2020. <br \/>\u00a0 \u00a0 \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1x165yGQt3p83zN4FnLM0CogUuKKe3SIRfWbD4Ht34XURUFws2A1HmmqSfsoYKLLAlmQJ4qrd0Ll_fyWaZNfFG6Xt224-KGqaQX0_H7O1jfoYaK4ys8bymQ3ugqHdlDVTctKW83yB5eX_XhyrHG0uTFWdta1qnLXsfzMIwodrh0oVYLmodSXDom2jDPNxAYN3u9IhxRYwITCUaP3M2QDHwSUABRyrYAwx-8zDqn37Dy1ClbEE3cWuDV08ynaHV6TI7n9qERX9808tVs1mvA9NxT2wM4tUVaVWdyM67lih8M=\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.neurologylive.com\/view\/celecoxib-oral-solution-gets-goahead-for-acute-migraine<\/u><\/a><\/p>\n<p>2)\u00a0 Source: Mordor Intelligence &#8211; MIGRAINE THERAPEUTICS MARKET (2020-2025)<\/p>\n<p>3)\u00a0 Source: Acute Migraine Headache: Treatment Strategies.<br \/>\u00a0 \u00a0 \u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=1x165yGQt3p83zN4FnLM0PJzdLOezZjd-eQimig4zXPMl6xKTv-6YMCpfh3ernvFXbsrtuoSdc5eeY047FUdDimurUFLBKsu0mlN33B7Sb7LPZNTzduomKxCY9dvhedKHd535EIJ8Rsyfha4TM3_LFnFP6p2DP-GwHe4_f6nVPy542V8OiOV56zMS5URQAWG\" rel=\"nofollow\" target=\"_blank\"><u>https:\/\/www.aafp.org\/pubs\/afp\/issues\/2018\/0215\/p243.html<\/u><\/a><\/p>\n<p>4)\u00a0 Data on file. Scilex Holding Company<\/p>\n<p>5)\u00a0 Lipton RB, et al. J Pain Res 2021; 14:549-560.<\/p>\n<p align=\"justify\">SEMDEXA\u2122 (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned.<\/p>\n<p align=\"justify\">ZTlido<sup>\u00ae<\/sup> is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company.<\/p>\n<p align=\"justify\">Gloperba<sup>\u00ae<\/sup> is the subject of an exclusive, transferable license to use the registered trademark by Scilex Holding Company.<\/p>\n<p align=\"justify\">ELYXYB<sup>\u00ae<\/sup> is a registered trademark owned by Scilex Holding Company.<\/p>\n<p align=\"justify\">All other trademarks are the property of their respective owners.<\/p>\n<p align=\"justify\">\u00a9 2025 Scilex Holding Company All Rights Reserved.<\/p>\n<p>      <img decoding=\"async\" alt=\"\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\" \/><br \/>\n      <br \/>\n      <img decoding=\"async\" alt=\"\" src=\"https:\/\/ml.globenewswire.com\/media\/NGFkYWQ0NGQtMDhhYS00ZGZmLWEwOTUtYmJlZTVlMGIxMDI1LTEyNjYyNzYtMjAyNS0wNC0xNS1lbg==\/tiny\/Scilex-Holding-Company.png\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>ELYXYB\u00ae is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it was found that migraine was more severe than other types of headaches and it impacted more than 2.7 million Canadians, with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.2 There is strong evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for migraine. ELYXYB\u00ae (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3 PALO ALTO, Calif., April 15, 2025 (GLOBE NEWSWIRE) &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-837478","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.8 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"ELYXYB\u00ae is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it was found that migraine was more severe than other types of headaches and it impacted more than 2.7 million Canadians, with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.2 There is strong evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for migraine. ELYXYB\u00ae (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3 PALO ALTO, Calif., April 15, 2025 (GLOBE NEWSWIRE) &hellip; Continue reading &quot;Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-15T13:11:51+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"8 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada\",\"datePublished\":\"2025-04-15T13:11:51+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/\"},\"wordCount\":1566,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/\",\"name\":\"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\",\"datePublished\":\"2025-04-15T13:11:51+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/","og_locale":"en_US","og_type":"article","og_title":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk","og_description":"ELYXYB\u00ae is a first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults.1 According to market data from 2018, it was found that migraine was more severe than other types of headaches and it impacted more than 2.7 million Canadians, with the Canadian migraine therapeutics market estimated to reach approximately $400 million by 2025.2 There is strong evidence for the use of non-steroidal anti-inflammatory drugs (NSAIDs) as a first-line treatment for migraine. ELYXYB\u00ae (celecoxib oral solution) is in the same class of agents, is fast acting, and has the potential to have the lowest gastrointestinal (GI) side effects of all NSAIDs.3 PALO ALTO, Calif., April 15, 2025 (GLOBE NEWSWIRE) &hellip; Continue reading \"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/","og_site_name":"Market Newsdesk","article_published_time":"2025-04-15T13:11:51+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"8 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada","datePublished":"2025-04-15T13:11:51+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/"},"wordCount":1566,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/","name":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=","datePublished":"2025-04-15T13:11:51+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQyMjE5NCM2ODY1OTU1IzIyNTQ3Mjc="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/scilex-holding-company-announces-approval-of-a-new-drug-submission-nds-from-the-health-canadas-pharmaceutical-drugs-directorate-bureau-of-cardiology-allergy-and-neurological-sciences-for\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Scilex Holding Company Announces Approval of a New Drug Submission (NDS) from the Health Canada\u2019s Pharmaceutical Drugs Directorate, Bureau of Cardiology, Allergy and Neurological Sciences for ELYXYB\u00ae\u2019s Acute Treatment of Migraine With or Without Aura in Canada"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837478","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=837478"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/837478\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=837478"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=837478"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=837478"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}